|
|
|
|
Although data on long-term effects on the maturing organ systems are lacking, the safety profile supports the safety and tolerability of interferon beta-1b (IFNB-1b) in children with multiple sclerosis and related diseases. All patients treated with IFNB-1b should undergo regular monitoring of liver function. |
|